גאלבוס 50 מ"ג

Country: Israel

Language: Hebrew

Source: Ministry of Health

Active ingredient:

VILDAGLIPTIN 50 MG

Available from:

NOVARTIS PHARMA SERVICES AG

ATC code:

A10BH02

Pharmaceutical form:

TABLETS

Administration route:

PER OS

Manufactured by:

NOVARTIS PHARMA STEIN AG, SWITZERLAND

Therapeutic group:

VILDAGLIPTIN

Therapeutic indications:

Galvus is indicated as an adjunct to diet and exercise in patients with type 2 diabetes mellitus• As monotherapy, if diet and exercise are not sufficient, or• In combination with metformin, or a sulfonylurea if treatment with these oral antidiabetics does not offer sufficient control of blood glucose.As triple oral therapy in combination with• a sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control. Galvus is also indicated for use in combination with insulin (with or without metformin) when diet and exercise plus a stable dose of insulin do not provide adequate glycaemic control.

Authorization date:

2013-11-01